title: Tissue factor pathway inhibitor levels in patients with homocystinuria.
abstract: Thrombotic events are a well-recognized complication of homocystinuria. However, the mechanisms involved in the atherogenic and thrombotic effects of homocyst(e)ine remain incompletely understood. The objective of this study was to determine the role of endothelial cell activation/damage as indicated by levels of thrombomodulin, tissue factor and tissue factor pathway inhibitor, and factor VII activity in patients with homocystinuria. Six patients with homocystinuria, nonresponsive to pyridoxine, treated only with trimethylglycine (betaine) were injected with a bolus of 20 IU/kg body weight of unfractionated commercial heparin to induce the release of tissue factor pathway inhibitor from the vascular endothelium. Tissue factor, thrombomodulin, and factor VII activity were measured by enzyme-linked immunosorbent assay and clotting assay before heparin administration. Tissue factor pathway inhibitor antigen and activity were measured before and 5 minutes after the bolus of heparin. Levels of homocyst(e)ine were elevated (patients: 144.2+/-19.2 micromol/L; controls: 10.2+/-0.9 micromol/L); however, levels of thrombomodulin, tissue factor, and tissue factor pathway inhibitor antigen were not statistically different from the control group. In contrast, tissue factor pathway inhibitor activity showed a significantly increased level (patients: 2.09+/-0.34 U/L; controls: 1.14+/-0.20 U/L; p<0.05) that was correlated with homocyst(e)ine. Factor VII activity was significantly decreased (patients: 64.7+/-5.1%; controls: 91.4+/-4.7%; p<0.05) and inversely correlated with homocyst(e)ine. After heparin the patients released higher amounts of tissue factor pathway inhibitor antigen and activity compared with the control group; however, the difference was not statistically significant. Although not treated with antithrombotic drugs, none of the patients had any thromboembolic complications after starting betaine. In addition to betaine treatment, the enhanced factor pathway inhibitor antigen activity observed in this small series of patients suggests that factor pathway inhibitor antigen may play an additional, as yet unexplained, role in this genetic disorder.
authors.affiliation: II Department of Medicine, University of Padua Medical School, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Cella
authors.forename: A
authors.initials: A
authors.lastname: Burlina
authors.forename: A
authors.initials: A
authors.lastname: Sbarai
authors.forename: G
authors.initials: G
authors.lastname: Motta
authors.forename: A
authors.initials: A
authors.lastname: Girolami
authors.forename: M
authors.initials: M
authors.lastname: Berrettini
authors.forename: W
authors.initials: W
authors.lastname: Strauss
mesh_terms: D000328:Adult; D001622:Betaine / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003541:Cystathionine beta-Synthase / Q000235:genetics; D004727:Endothelium / Q000293:injuries / Q000473:pathology; D005167:Factor VII / Q000378:metabolism; D005260:Female; D005343:Fibrinolytic Agents / Q000097:blood; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology; D006710:Homocysteine / Q000097:blood; D006712:Homocystinuria / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D006720:Homozygote; D006801:Humans; D008074:Lipoproteins / Q000097:blood* / Q000187:drug effects; D008297:Male; D011486:Protein C; D011736:Pyridoxine / Q000627:therapeutic use; D015842:Serine Proteinase Inhibitors / Q000097:blood; D018180:Thrombomodulin; D013925:Thromboplastin; D014652:Vascular Diseases; D014805:Vitamin B 12 / Q000235:genetics
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents; D008074:Lipoproteins; D011486:Protein C; D015842:Serine Proteinase Inhibitors; D018180:Thrombomodulin; C051928:lipoprotein-associated coagulation inhibitor; D006710:Homocysteine; D001622:Betaine; D005167:Factor VII; D006493:Heparin; D013925:Thromboplastin; D003541:Cystathionine beta-Synthase; D011736:Pyridoxine; D014805:Vitamin B 12